Acute kidney injury (AKI) is a common clinical condition that is associated with 31
significantly high rates of morbidity and mortality particularly in critically ill patients (1, 2, 32 10, 18). Despite fundamental advances in understanding the etiology and 33 pathophysiology of AKI the current therapeutic approaches remain limited to supportive 34 measures (e.g. dialysis). Treatment for AKI is confounded by several variables including 35 patient demographics, severity of AKI and AKI associated with complex medical and 36 surgical interventions. Therefore, there is a growing need to provide timely and 37 accurate diagnosis to allow for the implementation of potentially novel therapeutic 38 interventions to overcome AKI. 39
Studies in animal models of AKI have highlighted the therapeutic potential for a 40 number of interventions. However, translation of these potential therapies to humans 41 has yielded inconclusive and equivocal results (2, 5, 12) . One of the proposed reasons 42 for such failure is the lack of early markers for AKI and hence an unacceptable delay in 43 initiating therapy. In current clinical practice, identification and severity of AKI is 44 generally based on elevations in serum creatinine levels. Unfortunately, creatinine is an 45 unreliable indicator of early AKI for multiple reasons. For example, a significant 46 decrease (~50%) in GFR may be necessary to raise the serum creatinine above the 47 normal laboratory range (2, 9, 11). In sepsis, production of creatinine from the muscle is 48 reduced and relying on changes in serum creatinine to diagnose AKI in such settings 49 could delay diagnosis of AKI (3). Recent studies have conclusively shown that the 50 morbidity and mortality associated with AKI are correlated with the severity of kidney 51 injury. The data from these studies and animal models indicate that prevention or 52 decrease in the extent of injury could significantly lower negative outcomes related to AKI (6, 8, 9) . Therefore, there is a vital need for the identification of biomarkers that are 54 sensitive, specific and provide timely and early diagnosis of AKI before substantial 55 damage has already been done. 56
A biomarker is defined as a measurable and quantifiable biological parameter 57 that can serve as an index for health and physiology related assessment. An ideal 58 biomarker for AKI should be specific to the kidney, differentiate between subtypes of 59 AKI (prerenal, intrinsic renal and postrenal), determine the location and severity of injury 60 and most importantly, facilitate early detection of AKI for successful utilization of 61 potential therapeutic agents. In addition, the test should be inexpensive, non-invasive, 62 accurate, easy and rapid to quantify (7, 8, 11) . Extensive ongoing research has yielded 63 several potential biomarkers in AKI including neutrophil gelatinase-associated lipocalin 64 (NGAL), liver fatty acid binding protein (L-FABP), kidney injury molecule-1 (KIM-1), 65 interleukin-18, netrin, monocyte chemoattractant protein-1, cystatin C as well as others 66 (4, 7, 10, 13, 16) . 67
In the present issue, Ware and colleagues highlight the importance of urine 68 albumin as a biomarker of AKI (17). Use of albumin excretion has been well established 69 as a diagnostic and prognostic marker to evaluate the degree of severity of glomerular 70 diseases in the progression of chronic kidney disease (14, 15), but only limited studies 71 have suggested the utility of urine albumin as a biomarker for AKI. Using multiple 72 complementary approaches involving five animal models of AKI in mice (three 73 representing renal causes of AKI, one for pre-renal and one for post-renal) the authors 74
show that urine albumin increases as early as 4h following injury only in the intrinsic 75 renal causes of AKI (ischemia reperfusion, nephrotoxin and rhabdomyolysis) and not ineither pre-renal (secondary to endotoxin) or postrenal (obstructive uropathy) conditions. 77
Increases in urine albumin occurred prior to changes in serum creatinine, which 78 increased only after significant azotemia had developed. These results from animal 79 models of AKI were further corroborated in urine samples from patients with and without 80 AKI and found to be comparable to early changes in NGAL, an extensively validated 81 AKI biomarker. The findings in this work are consistent with recent studies published in 82 rat models of nephrotoxin-induced AKI (19). In the course of investigating urinary trefoil 83 factor 3 as a biomarker (which was significantly decreased in nephrotoxin-induced AKI), 84
Yu and colleagues found urine albumin to outperform serum creatinine and blood urea 85 nitrogen for detecting acute tubular injury in rats. These studies also evaluated 86 isoproterenol toxicity to the heart and skeletal muscle where no renal histological 87 damage occurs and found no change in urinary albumin levels. These results and the 88 work by Ware and colleagues further substantiate the specificity of urine albumin as a 89 biomarker for AKI. 90
The findings in this work also provide new insights into the regulation of the 91 albumin gene, which is normally silenced in the kidney. During AKI secondary to 92 intrinsic renal causes, there is significant proximal tubular injury. One potential 93 consequence of such tubular injury would be the inability of the proximal tubule to 94 reabsorb albumin, resulting in albuminuria. The authors provide an additional 95 mechanism in this regard that relates to direct increases in albumin gene transcription in 96 the renal cortex in the animal models of intrinsic AKI. Chromatin immunoprecipitation 97 analysis revealed an association of RNA polymerase II with the albumin gene, indicating 98 an increase in the transcriptional activation of albumin, which was also observed inurine samples from patients with AKI. A 5-fold increase in RNA polymerase II binding to 100 urinary fragments of the albumin gene was detected in patients with AKI compared to 101 control subjects without AKI. An increase in the expression of an albumin-like gene, a-102 fetoprotein was also noted. Assessment of serum albumin levels would provide further 103 information on the contribution of albumin gene transcription to increased urine albumin 104 levels, described in this work. The authors suggest an interesting analogy for this 105 phenomenon of increased generation of albumin and a-fetoprotein and have termed this 106 as "renal hepatization" during AKI, a potentially new avenue in AKI research. 107
The strengths of this paper include the validation of urinary albumin as a specific 108 biomarker for intrinsic renal causes of AKI as opposed to most other promising 109 biomarkers that are unable to accurately differentiate the etiology of AKI. Moreover, the 110 use of AKI and non-AKI associated patient samples provides strong evidence for the 111 use of this biomarker in clinical practice. Of note, even the ICU patients without AKI had 112 a modest increase in urine albumin, which may suggest subclinical kidney injury. It 113 would be interesting to follow these patients and determine if urine albumin increases 114 over time and if they develop AKI. In the future, it will be essential to validate the 115 sensitivity and specificity of urine albumin in clinical samples from larger cohorts and 116 from multiple clinical settings. Although it is not clear from the animal models if levels of 117 urine albumin could predict the severity of AKI, it may be important to evaluate this in a 118 clinical setting. Further studies should also evaluate if urine albumin can serve as a 119 prognostic marker and its use to evaluate outcomes following therapeutic interventions. 120
In conclusion, it is evident that urine albumin may serve as a biomarker for early 121 diagnosis of AKI. It is specific to intrinsic causes of AKI and is not altered in pre-renal orpost-renal causes of AKI. The commercial availability of tests for the detection of urine 123 albumin and its low cost gives it an added advantage for routine clinical use. In clinical 124 practice however, the use of a single biomarker may not always be sufficient. As 125 highlighted by several investigators in the literature, a panel of biomarkers would be 126 necessary to identify the severity of injury, the type of insult and also monitor response 127 to therapeutic interventions. 
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